Skip Navigation
Menu
ACP Journal Club |16 September 2008

Prasugrel reduced ischemic outcomes more than did clopidogrel in patients receiving stents for ACS

William B. Hillegass, MD, MPH; Brigitta C. Brott, MD

Article, Author, and Disclosure Information
FULL TEXT
Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371:1353-63. 18377975

Cardiology:

In ex vivo aggregation, prasugrel is a more rapid, consistent, and potent P2Y12 adenosine diphosphate platelet-receptor antagonist than clopidogrel (1). A 300-mg loading dose of clopidogrel requires ≥ 6 and up to 18 hours to achieve maximum clinical benefit (2). Even with an optimal 600-mg loading dose of clopidogrel,...
FULL TEXT
PDF
Not Available
Citations
Citation

Hillegass WB, Brott BC. Prasugrel reduced ischemic outcomes more than did clopidogrel in patients receiving stents for ACS. Ann Intern Med. 2008;149:JC3–12. doi: 10.7326/0003-4819-149-6-200809160-02012

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2008;149(6):JC3-12.

DOI: 10.7326/0003-4819-149-6-200809160-02012

0 Citations

Related Articles
Prasugrel prevented ischemic events compared with clopidogrel in patients having PCI for STEMI
Annals of Internal Medicine; 150 (12): JC6-10
Management of Patients Undergoing Percutaneous Coronary Revascularization
Annals of Internal Medicine; 139 (2): 123-136
Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
Annals of Internal Medicine; 160 (4): 221-232
Cangrelor reduced ischemic PCI complications more than clopidogrel without increasing severe bleeding
Annals of Internal Medicine; 158 (12): JC5
View MoreView Less

Journal Club
Prasugrel prevented ischemic events compared with clopidogrel in patients having PCI for STEMI
Annals of Internal Medicine; 150 (12): JC6-10
Cangrelor reduced ischemic PCI complications more than clopidogrel without increasing severe bleeding
Annals of Internal Medicine; 158 (12): JC5
Review: Reduced function CYP2C19 genotypes may increase risk for stent clots in patients receiving clopidogrel
Annals of Internal Medicine; 155 (12): JC6-13
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events
Annals of Internal Medicine; 167 (6): JC28
View MoreView Less

Related Point of Care
Stable Ischemic Heart Disease
Annals of Internal Medicine; 171 (3): ITC17-ITC32
View MoreView Less

Related Topics
Acute Coronary Syndromes
Cardiology
Coronary Heart Disease
Emergency Medicine

Acute Coronary Syndromes, Cardiology, Coronary Heart Disease, Emergency Medicine.

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×